评估美国男性性健康状况保险覆盖透明度的差异性
本研究检索美国84家最大健康保险计划的公开政策文件,评估男性性健康(勃起功能障碍和性腺功能减退)保险覆盖透明度。乳房重建政策94%公开可查,而晚期ED治疗选项仅39%、性腺功能减退仅62%公开。在有ED覆盖数据的计划中,85%认为阴茎假体和海绵体内注射医学必要;91%认为雄激素替代医学必要。
要点
- 84家美国大型保险计划中,乳房重建政策公开率94%,晚期ED仅39%,性腺功能减退62%。
- 有ED覆盖数据的计划中,85%认为阴茎假体和海绵体内注射医学必要。
- 有性腺功能减退覆盖数据的计划中,91%认为雄激素替代医学必要。
核心结论
- 与乳房重建手术形成鲜明对比,保险公司对ED和性腺功能减退的覆盖缺乏透明度。
研究设计与样本
- 横断面研究,检索美国84家最大健康保险计划的公开政策文件,设定2例索引患者:1例磷酸二酯酶5型抑制剂难治性ED需海绵体内注射或阴茎假体,1例50岁男性实验室确诊症状性性腺功能减退需睾酮替代治疗(按内分泌学会标准),以乳房切除术后乳房重建为对照。
主要发现
- 在84家最大健康保险计划中,乳房重建政策公开可查率为94%,晚期ED治疗选项政策公开率为39%,性腺功能减退政策公开率为62%。
- 在有ED覆盖公开数据的计划中,85%认为阴茎假体和海绵体内注射医学必要;在有性腺功能减退覆盖数据的计划中,91%认为索引患者的雄激素替代医学必要。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To determine the degree of transparency of health insurance policies regarding coverage of male sexual health conditions, we examined the publicly available policy coverage documents of the largest U.S. medical insurance plans. METHODS: We selected 2 index patients across the male sexual health spectrum: (1) a phosphodiesterase type 5 refractory erectile dysfunction (ED) patient requiring intracavernosal injection therapy or penile prosthesis and (2) a 50-year-old male patient with laboratory-confirmed, symptomatic hypogonadism requiring testosterone replacement therapy as defined by endocrine society criteria. We researched the policy documents regarding coverage for standard therapies. We used breast reconstruction after mastectomy as a control. RESULTS: We queried the publicly available policy statements for 84 of the largest health-care plans in the United States. Whereas breast reconstruction policies are publicly available for 94% of the plans examined, policies of only 39% of the plans for advanced ED treatment options and 62% for hypogonadism are publicly available. Of the plans that had publicly accessible data for ED coverage, 85% viewed penile prosthesis and intracavernosal injection as medically necessary, whereas 91% viewed androgen replacement as medically necessary for our index patient. CONCLUSION: There is a lack of transparency among medical insurers regarding coverage of ED and hypogonadism in stark contrast to reconstructive breast surgery.
引用
- Le B, McAchran S, Paolone D, et al. Assessing the Variability in Insurance Coverage Transparency for Male Sexual Health Conditions in the United States. Urology. 2016. PMID: 28024968. doi:10.1016/j.urology.2016.12.031
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。